Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

MK-3102

Merck turns to gamification in diabetes

Working with Ayogo on mobile app to improve adherence

- PMLiVE

AstraZeneca buys BMS out of diabetes alliance

Will spend up to $4.3bn to secure sole rights to Onglyza and Forxiga

- PMLiVE

J&J’s combo diabetes drug held up by FDA

Regulator wants more dosing data on canaglifozin / metformin product

- PMLiVE

FDA backs a brace of allergy immunotherapies

Merck & Co and Stallergenes win drug approvals in US

- PMLiVE

Police to probe Novo Nordisk over disclosure delay

Regulator says pharma company was late to announce FDA decision to not approve Tresiba and Ryzodeg

- PMLiVE

Study highlights poor diabetes consultation

Less than a third of patients asked for input into their treatment plans

Sanofi reception

Sanofi’s Lantus successor on track

Positive late-stage data for U300 insulin in type 2 diabetes patients

- PMLiVE

FDA backs new formulation of Noxafil

Merck wins US approval for delayed-release version of anti-infective

- PMLiVE

Sanofi wins two at PMEA 2013

Awards haul also includes four high commendations

- PMLiVE

FDA lifts restrictions on Avandia use

US regulator says GSK’s diabetes drug does not increase heart attack risk

- PMLiVE

BMS/AZ’s diabetes drug among CHMP recommendations

Xigduo one of six new drugs backed in EU

Eli Lilly HQ

Lilly exploring diabetes portfolio for Alzheimer’s potential

Undertakes pre-clinical investigations as it monitors the area

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links